Skip to main content

Table 2 Distributions of tumor characteristics in Kenyan breast cancer patients, overall and by hospitals (N=838)

From: Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya

Tumor characteristic Overall (n=838) Hospitals
AKU (n=350, 42%) Kijabe (n=105, 13%) Nyeri (n=110, 13%) St Mary’s (n=122, 15%) Others (n=151, 18%)  
N % N % N % N % N % N % P*
Tumor subtypes
ER status
  Negative 256 30.6 101 28.9 25 23.8 45 40.9 32 26.2 53 35.1 0.029
  Positive 582 69.5 249 71.1 80 76.2 65 59.1 90 73.8 98 64.9  
PR status
  Negative 340 40.6 138 39.4 36 34.3 50 45.5 48 39.3 68 45.0 0.36
  Positive 498 59.4 212 60.6 69 65.7 60 54.5 74 60.7 83 55.0  
HER2 status
  Negative 596 72.6 246 71.3 75 72.1 81 76.4 91 74.6 103 71.5 0.84
  Positive 225 27.4 99 28.7 29 27.9 25 23.6 31 25.4 41 28.5  
  Missing 17   5   1   4   0   7   
Tumor molecular subtype
  Luminal Aa 286 34.8 121 35.1 46 44.2 37 34.9 40 32.8 42 29.2 0.080
  Luminal B 294 35.8 127 36.8 33 31.7 26 24.5 52 42.6 56 38.9  
  HER2-enriched 88 10.7 37 10.7 11 10.6 14 13.2 12 9.8 14 9.7  
  Triple negative 153 18.6 60 17.4 14 13.5 29 27.4 18 14.8 32 22.2  
  Missing 17   5   1   4   0   7   
  Luminal Aa 286 36.9 121 36.7 46 48.9 37 37.4 40 33.9 42 31.1 0.094
  Luminal B - HER2- 157 20.2 65 19.7 15 16.0 15 15.2 33 28.0 29 21.5  
  Luminal B - HER2+ 137 17.7 62 18.8 18 19.1 11 11.1 19 16.1 27 20.0  
  HER2-enriched 88 11.3 37 11.2 11 11.7 14 14.1 12 10.2 14 10.4  
  Core-basal like 57 7.3 24 7.3 2 2.1 13 13.1 7 5.9 11 8.1  
  Five negative 51 6.6 20 6.4 2 2.1 9 9.1 7 5.9 12 8.9  
  Missing 62b   20   11   11   4   16   
Tumor pathology
Surgery
  Core biopsy only 435 51.9 157 44.9 26 24.8 46 41.8 73 59.8 133 88.1 < 0.0001
  Lumpectomy or mastectomy 403 48.1 193 55.1 79 75.2 64 58.2 49 40.2 18 11.9  
Tumor size (cm)
  < 2 41 7.6 29 13.1 8 8.1 2 2.3 1 1.9 1 1.3 < 0.0001
  2–< 5 287 53.5 134 60.4 53 53.5 39 44.8 26 50.0 35 45.5  
  ≥ 5 209 38.9 59 26.6 38 38.4 46 52.9 25 48.1 41 53.3  
  Missingc 301   128   6   23   70   74   
Tumor overall grade
  Grade 1 (low) 35 5.0 20 7.3 4 4.4 6 5.7 2 1.7 3 2.8 0.17
  Grade 2 (intermediate) 319 45.9 130 47.3 34 37.8 44 41.5 59 50.9 52 48.2  
  Grade 3 (high) 341 49.1 125 45.5 52 57.8 56 52.8 55 47.4 53 49.1  
  Missing/not applicable 143   75   15   4   6   43   
Lymphovascular invasion
  No 326 38.9 139 39.7 30 28.6 34 30.9 47 38.5 76 50.3 0.0029
  Yes 512 61.1 211 60.3 75 71.4 76 69.1 75 61.5 75 49.7  
Among cases with lumpectomy or mastectomy (n=403):
Tumor stage
  Stage 0, i 30 8.2 21 12.1 2 2.6 6 10.3 1 2.4 0 0.0 0.0040
  Stage ii 154 42.3 85 49.1 30 39.5 20 34.5 12 29.3 7 43.8  
  Stage iii, iv 180 49.5 67 38.7 44 57.9 32 55.2 28 68.3 9 56.3  
  Missing 39   20   3   6   8   2   
Lymph nodes with metastasis
  No 162 40.2 89 46.1 23 29.1 22 34.4 20 40.8 8 44.4 0.96
  Yes 241 59.8 104 53.9 56 70.9 42 65.6 29 59.2 10 55.6  
Extranodal extension
  No 244 60.6 132 68.4 39 49.4 35 54.7 26 53.1 12 66.7 0.022
  Yes 159 39.5 61 31.6 40 50.6 29 45.3 23 46.9 6 33.3  
  1. * P values were computed from chi-square test except where noted. P values less than 0.05 are shown in bold font. a Seventy-four cases, who had missing data for both ki67 and tumor grade, were grouped into the subcategory “Luminal A” in tumor molecular subtype. bSixty-two cases whose tumor molecular subtype cannot be determined: 17 cases are due to their missing HER2 status; the other 45 cases are due to their missing CK5/6 and EGFR status. c Ninety-eight percent of missingness are from cases with core biopsy only. AKU, Aga Khan University; CK5/6, cytokeratin 5/6; EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; PR, progesterone receptor